Page 91 - Sohini Das

AstraZeneca resumes clinical trials in UK after green signal

Meanwhile, DCGI asks Serum Institute to submit DSMB UK and India data to resume trials, after asking it to stop recruiting volunteers on Friday

Bharat Biotech's Covaxin succeeds in challenge trials on Rhesus monkeys

The results showed protective efficacacy, increasing Sars-CoV-2 specific IgG and neutralising antibodies reducing the replication of the virus in the nasal cavity, throat and lung tissues of monkey

Kochi firm gets nod to test India's first novel molecule for Covid-19

PNB Vesper's drug developed from 12 years of research for small-cell lung cancer (for which it is under trial) has shown positive response in Covid-19, the firm claims

Innovative therapy for coronavirus is required as much as a vaccine

Pharma giants have already started work on different formulations and combination therapies of their existing molecules

Unlock 4.0: User industries turn to innovations as economy opens up further

A gamechanger for offices and factories in the country, the Shycocan, which can clear an area of 1000 square feet from coronaviruses, was discovered by accident

Diagnostic labs pin hopes on Covid-19 test bouquets to revive revenues

Non-Covid revenues are back to 80% of Jan levels. Some expect demand to be 1.2 times pre-Covid level by Diwali

Remdesivir prices may rise after Gilead gets full authorisation from USFDA

In August, Gilead filed an application with the US Food and Drug Administration (USFDA) seeking full approval for remdesivir (Veklury)

Towards a new India: New e-health database rolls out via pilot projects

Modi's Independence Day speech focused on areas such as health and infra for a self-reliant New India. The first of a three-part series looks at the implications of the proposed Digital Health Mission

Health Ministry's guide for Covid-19 treatment drops itolizumab drug

FAQs for clinical management prepared by AIIMS and MoHFW says evidence for Favipiravir is weak

Covid-19 prescription: Pharma players shift their focus over the counter

The pandemic pushes pharma companies to look at drugs that held promise in transitioning to over the counter segment

Experts suggest policy changes to boost coronavirus research & development

Funding Covid-related research now included in CSR spends

When will India finally have access to coronavirus vaccine?

India commands 40 per cent of global capacity for vaccines which is estimated at 5.7 billion doses

In the works: Priority list of who gets the Covid-19 vaccine first

Expert group preparing the list also in touch with both local and MNC vaccine makers

Govt sets ball rolling on NDHM, comes out with draft policy on health data

The provisions of this policy shall apply to the entities involved in the NDHM and those who are a part of the NDHE

Indian players in two minds about collaboration on Russian vaccine

Russia reached out to India, players are open to collaborate but seek clarity on data

Covid-19 drug sales shine even as domestic pharma market slows down

Major therapy areas show decline or low single-digit growth

Centre sets ball rolling on Covid vaccine procurement, may hold meet Monday

Health care experts said it was about time the government set the ball rolling for scaling up manufacturing because there would not be much time left after the world had a vaccine candidate

Fortis slips into red in Q1, posts loss before tax of Rs 208.26 crore

Total income during the quarter fell by 47 per cent to Rs 610 crore

Fortis to be renamed Parkway to distance itself from Singh brothers

License agreement of Fortis, SRL brands expire in 2021

Hyderabad-based Biological E joins hands with J&J for Covid-19 vaccine

The vaccine candidate is in phase 1/2a clinical trials